Peptide basics

Sermorelin is FDA-approved and has no registered trials. Both are true.

This page explains why one compound's records look the way they do. It does not describe what sermorelin was approved for, does not discuss dosing or administration in any form, and makes no statement about whether it is appropriate for anyone.

Two records that look contradictory

Search Drugs@FDA for sermorelin and you find application NDA019863, brand name GEREF, active ingredient sermorelin acetate, sponsor EMD Serono. The submission history shows an original approval dated 28 December 1990 and approved supplements in May 1991, August 1991, March 1998, April 1998 and October 2001.¹²

Search ClinicalTrials.gov for sermorelin as an intervention and you find nothing. Not a small number — none. Under the rule this site applies, that a study counts only when the compound is named in an intervention field, the count is zero.⁵

Both are accurate, and the reconciliation is entirely a matter of dates.

The chronology

GEREF was approved in December 1990. The earliest study records posted to ClinicalTrials.gov date from 1999, and fewer than 2,200 records had been posted in total by the end of 2000. The obligation to register applicable clinical trials arrived with Title VIII of the Food and Drug Administration Amendments Act of 2007, and the final rule detailing what must be submitted took effect on 18 January 2017.³⁴⁹

So the studies that supported this approval were designed, run, submitted and reviewed a decade before a public registry existed to receive them, and twenty-six years before anyone was required to file one. There is no gap in the evidence here. There is a gap in a database that did not exist yet, which is a different object entirely.³⁴

What the raw search actually returns

A loose intervention search for sermorelin does return studies — a couple of dozen of them. Opening each one shows why none is counted: they are studies of growth hormone releasing hormone, of GHRH plus arginine as a diagnostic stimulation test, and above all of tesamorelin, which appears repeatedly under its own name and its sponsor code TH9507. NCT02196831, a study of tesamorelin's effects on liver fat in HIV, is typical of the set.⁵⁶

This is the failure mode the intervention-name rule exists to catch. Sermorelin is a GHRH analogue, so any search on its name pulls in the entire GHRH literature. Reporting those as sermorelin trials would inflate the count by a couple of dozen studies of other molecules, and would be the exact error this site's method was written to prevent.⁵

What the record does contain

Roughly 330 PubMed records return for the name sermorelin, though as with any raw term count that total includes reviews, animal work and passing mentions. Restricted to title or abstract over the last decade the annual counts are in the low single digits, which describes a compound the literature has largely finished with rather than one it is working on.⁷

The approval itself is the substantial part of the record. An NDA is granted on a submitted body of evidence that the agency reviewed, and the fact that the review happened is durable regardless of whether the underlying studies are findable in a registry today. What a reader cannot easily do is read those studies, because pre-registry trial reports are scattered, often unpublished, and not indexed against the application.¹³

Discontinued does not mean withdrawn

The product's marketing status on the FDA record is Discontinued. The strength field on the same record carries a note that a Federal Register determination found the product was not discontinued or withdrawn for safety or effectiveness reasons.¹

That distinction is load-bearing and routinely lost. Products leave the market for commercial reasons far more often than for safety ones, and the FDA records the difference precisely because the two would otherwise be indistinguishable to anyone reading the database.¹²

Why this site grades it the way it does

The market table on this site grades sermorelin E, a grade used for exactly one situation: an approved product with an empty registry record. It is not the top grade, because an approval alone next to a study count of zero cannot honestly render as strong evidence in a column headed how much is known. It is not the bottom grade either, because a full NDA review is not nothing.¹⁵

The general lesson generalises past this one compound. Registry counts are a good instrument with a known blind spot, and the blind spot is everything that happened before 2000. Any compound with an approval older than the registry will show the same pattern, and reading it as an evidence gap gets the history backwards.³⁴⁸